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Dear Editor
I read with great interest the article by Wang and 
colleagues (Wang et al., 2014), which investigated 
the impact of Stathmin 1 expression in outcome of a 
cohort with 100 esophageal carcinoma patients and 
found that high levels of Stathmin 1 was associated with 
low differentiated tumors, invasion, metastasis, higher 
tumor grade and negatively impacted survival. Several 
studies converge with the findings reported by Wang 
and colleagues and provide important evidences of the 
participation of Stathmin 1 in malignant phenotype of 
esophageal carcinoma. 
Stathmin 1 (also known as Oncopotein 18, OP18) is 
a polypeptide with 18 kDa, which acts as a microtubule-
destabilizing protein, integrates multiple signaling 
pathways, and providing cell cycle progression, survival 
and migration (Belletti and Baldassarre, 2011). The first 
evidence that Stathmin 1 has a role esophageal carcinoma 
was the identification of a gain-of-function mutation in 
STMN1 gene (Q18E) in esophageal carcinoma samples, 
and its mutation presented a potential for in vitro and 
in vivo malignant transformation (Misek et al., 2002). 
Latterly, Holmfeldt and colleagues reported that STMN1 
Q18E mutation contributes to chromosomal instability 
(Holmfeldt et al., 2006).
Using 2-DE and immunohistochemistry analysis, Liu 
and colleagues (Liu et al., 2013) reported that Stathmin 
1 was highly expressed in 101 out of 143 esophageal 
carcinoma samples and found an association with the 
tumor grade: high Stathmin 1 expression was found 
in the highest tumor grade. Interestingly, Stathmin 1 
silencing reduced the migration capacity of the esophageal 
carcinoma cell lines (Liu et al., 2013). Accordingly, 
studies performed by Wang and colleagues (Wang et al., 
2011) and by Akhtar and colleagues (Akhtar et al., 2014b) 
demonstrated that Stathmin 1 silencing is able to reverse 
the malignant phenotype of esophageal carcinoma cells, 
including reduced cell proliferation, cell cycle progression, 
migration, invasion and tumorigenicity, and increased 
apoptosis.
Recently, Akhtar and colleagues (Akhtar et al., 2014a; 
Akhtar et al., 2014b) also provides additional evidences 
of Stathmin 1 role in the esophageal carcinoma. Stathmin 
1 overexpression was found in 100 out of 174 pN0 
esophageal carcinoma patients and Stathmin 1 was an 
independent predictor factor for lymphatic metastasis 
recurrence (Akhtar et al., 2014a). In addition, Stathmin 
1 overexpression was observed 31 out of 63 distal 
esophageal adenocarcinoma patients and it was associated 
with lymph node metastasis and high tumor grade (Akhtar 
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et al., 2014b). 
In order to verify whether Stathmin 1 could be a 
target in cancer, several groups have proposed different 
approaches in attempts to inhibit Stathmin 1 function in 
vivo and the results have been promises. For instance, the 
GDP366, a dual inhibitor for Stathmin 1 and Survivin, 
reduced dramatically the malignant phenotype of cancer 
cells in vitro and in vivo (Shi et al., 2010). In another study, 
Phadke and colleagues (Phadke et al., 2011), using small 
hairpin RNA approach in vivo, showed that inhibition of 
Stathmin 1 reduced xenograft tumor growth in a mice 
model. Accordingly, Akhtar and colleagues (Akhtar et al., 
2014c) tested the local injection of lentivirus-delivered 
shRNA targeting Stathmin 1 as approach, and found a 
significant regression in the cell growth of pre-established 
xenograft tumors in mice.
Collectively, these studies point out Stathmin 1 as a 
potential prognosis marker and a promising therapeutic 
target in esophageal carcinoma. Although novel strategies 
targeting in Stathmin 1 had been developed and applied 
to other types of cancer, the application of these strategies 
in the esophageal carcinoma models are of interest and 
require future investigation.
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